Stattin P - Search Results

1

A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.

Licciardello MP, Ringler A, Markt P, Klepsch F, Lardeau CH, Sdelci S, Schirghuber E, Müller AC, Caldera M, Wagner A, Herzog R, Penz T, Schuster M, Boidol B, Dürnberger G, Folkvaljon Y, Stattin P, Ivanov V, Colinge J, Bock C, Kratochwill K, Menche J, Bennett KL, Kubicek S. Licciardello MP, et al. Among authors: stattin p. Nat Chem Biol. 2017 Jul;13(7):771-778. doi: 10.1038/nchembio.2382. Epub 2017 May 22. Nat Chem Biol. 2017. PMID: 28530711

2

Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P. Vellekoop A, et al. Among authors: stattin p. J Urol. 2014 Feb;191(2):350-7. doi: 10.1016/j.juro.2013.09.034. Epub 2013 Sep 23. J Urol. 2014. PMID: 24071481

3

Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer.

Plym A, Folkvaljon Y, Garmo H, Holmberg L, Johansson E, Fransson P, Stattin P, Lambe M. Plym A, et al. Among authors: stattin p. J Sex Med. 2014 Aug;11(8):2100-8. doi: 10.1111/jsm.12586. Epub 2014 May 26. J Sex Med. 2014. PMID: 24862360

4

Five-year nationwide follow-up study of active surveillance for prostate cancer.

Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. Loeb S, et al. Among authors: stattin p. Eur Urol. 2015 Feb;67(2):233-8. doi: 10.1016/j.eururo.2014.06.010. Epub 2014 Jun 30. Eur Urol. 2015. PMID: 24993868 Free PMC article.

5

Upper limit of cancer extent on biopsy defining very low-risk prostate cancer.

Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. Bratt O, et al. Among authors: stattin p. BJU Int. 2015 Aug;116(2):213-9. doi: 10.1111/bju.12874. Epub 2015 Mar 7. BJU Int. 2015. PMID: 25053197

6

Causes of death in men with localized prostate cancer: a nationwide, population-based study.

Van Hemelrijck M, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, Stattin P. Van Hemelrijck M, et al. Among authors: stattin p. BJU Int. 2016 Mar;117(3):507-14. doi: 10.1111/bju.13059. Epub 2015 May 15. BJU Int. 2016. PMID: 25604807 Free PMC article.

7

Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P. Loeb S, et al. Among authors: stattin p. JAMA. 2015 Jun 23-30;313(24):2449-55. doi: 10.1001/jama.2015.6604. JAMA. 2015. PMID: 26103029

8

Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study.

Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P. Thomsen FB, et al. Among authors: stattin p. Int J Cancer. 2016 May 1;138(9):2154-60. doi: 10.1002/ijc.29961. Epub 2016 Jan 18. Int J Cancer. 2016. PMID: 26662367

9

Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Loeb S, et al. Among authors: stattin p. Eur Urol. 2016 Jun;69(6):1135-41. doi: 10.1016/j.eururo.2015.11.036. Epub 2015 Dec 17. Eur Urol. 2016. PMID: 26707871 Free PMC article.

10

Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P. Loeb S, et al. Among authors: stattin p. Eur Urol. 2016 Nov;70(5):824-828. doi: 10.1016/j.eururo.2015.12.013. Epub 2015 Dec 29. Eur Urol. 2016. PMID: 26743040 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

521 results

Search Page

Filters